高级检索
当前位置: 首页 > 详情页

Peptidomics Analysis Reveals Peptide PDCryab1 Inhibits Doxorubicin-Induced Cardiotoxicity

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ EI

机构: [1]Nanjing Med Univ, Dept Cardiol, Affiliated Hosp 1, Nanjing 210029, Peoples R China [2]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Gen Practice, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China [3]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Cardiol, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China
出处:
ISSN:

摘要:
Doxorubicin (DOX) is limited due to dose-dependent cardiotoxicity. Peptidomics is an emerging field of proteomics that has attracted much attention because it can be used to study the composition and content of endogenous peptides in various organisms. Endogenous peptides participate in various biological processes and are important sources of candidates for drug development. To explore peptide changes related to DOX-induced cardiotoxicity and to find peptides with cardioprotective function, we compared the expression profiles of peptides in the hearts of DOX-treated and control mice by mass spectrometry. The results showed that 236 differential peptides were identified upon DOX treatment, of which 22 were upregulated and 214 were downregulated. Next, we predicted that 31 peptides may have cardioprotective function by conducting bioinformatics analysis on the domains of each precursor protein, the predicted score of peptide biological activity, and the correlation of each peptide with cardiac events. Finally, we verified that a peptide (SPFYLRPPSF) from Cryab can inhibit cardiomyocyte apoptosis, reduce the production of reactive oxygen species, improve cardiac function, and ameliorate myocardial fibrosis in vitro and vivo. In conclusion, our results showed that the expression profiles of peptides in cardiac tissue change significantly upon DOX treatment and that these differentially expressed peptides have potential cardioprotective functions. Our study suggests a new direction for the treatment of DOX-induced cardiotoxicity.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 2 区 生物
小类 | 3 区 细胞生物学
最新[2025]版:
JCR分区:
出版当年[2018]版:
Q2 CELL BIOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Nanjing Med Univ, Dept Cardiol, Affiliated Hosp 1, Nanjing 210029, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Nanjing Med Univ, Dept Cardiol, Affiliated Hosp 1, Nanjing 210029, Peoples R China [3]Shanghai Jiao Tong Univ, Tongren Hosp, Dept Cardiol, Sch Med, 1111 Xianxia Rd, Shanghai 200336, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23459 今日访问量:6 总访问量:1282 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)